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Viral loadAbstract Background: Hepatitis C virus is considered to be one of the most important devastating
causes of chronic hepatitis, cirrhosis, and hepatic cellular carcinoma. Toll-like receptor 7 (TLR7) is
a pathogen-recognition receptor that is expressed on innate immune cells. It recognizes viral RNA
which induces its activation with a subsequent increase in IFN-a transcription. It has been postu-
lated that HCV may cause down regulation of these receptors as one of immune evading mecha-
nisms that participate in viral persistence.
The aim of the work: Was to investigate the expression of TLR7 in peripheral blood of patients
with chronic HCV infections and patients with HCC, comparing it with normal individuals, and
correlating it with both serum levels of IFN-a and viral load.
Results: The results of this study showed a signiﬁcant decrease in TLR7 expression in patients
with chronic HCV and no detection at all in patients with HCC, in addition a signiﬁcant negative
correlation was observed between levels of TLR7expression and interferon a when compared to
viral load.
Conclusion: Down regulation of TLR7 expression in HCV and HCC patients may contribute to
the decrease of IFN-a and increase in viral load. These results raise the possibility that by targeting
TLR7 with high afﬁnity pharmacological stimulants may be able to control HCV infection by
induction of IFN-a and direct activation of antiviral mechanisms in hepatocytes. Additionally, they
provide insight about the potential use of TLR7 as a new set of molecular markers for prognosis
and outcomes of chronic HCV infection and HCC.
 2014 Production and hosting by Elsevier B.V. on behalf of Ain Shams University.1. Introduction
Hepatitis C virus infection has become a global problem neces-
sitating a wide range of control and preventive measures. It is a
388 T.A. Abdel-Raouf et al.member of the Flaviviridae family, which is a small enveloped
positive sense single stranded RNA virus [1]. Approximately
130–150 million people globally have chronic hepatitis C
infection, and from 350,000 to 500,000 people die from hepa-
titis C-related liver diseases each year [2].
HCV is immunogenic and triggers immune responses in
most healthy adults. Intrinsic components of the virus presum-
ably activate the innate immune system that effectively limits
viral replication. One of the earliest responses to HCV is the
production of type I-IFNs, critical cytokines that establish
an antiviral state and bridge the innate and adaptive immune
systems [3].
Toll-like receptors (TLRs), which belong to a family of
pathogen recognition receptors, are an essential part of the
innate immune response that detects conserved pathogen-
associated molecular patterns (PAMPs) of bacteria, parasites,
fungi, protozoa components, and viruses.[4] They are
expressed by a variety of immune and non-immune cells, such
as B lymphocytes, T lymphocytes, antigen-presenting cells, and
ﬁbroblastic synoviocytes [5].
TLR7 is mainly expressed in the endosome-lysosome mem-
brane of plasmacytoid dendritic cells (pDCs), B lymphocytes,
hepatic natural killer cells, and virally infected hepatocytes.
In these cells, endosomal proteases digest HCV particles,
uncoating and releasing viral ssRNA which is recognized by
TLR7 [6].
TLR7 is interesting in regard to HCV-infection, because its
engagement leads to production of increased levels of inter-
feron-a [7]. Stimulation of TLR7 induces recruitment of mye-
loid differentiation factor 88 (My D 88) which in turn recruits
members of the interleukin-1 (IL-1) receptor-associated kinase
4 (IRAK4) family that associates temporarily with a member
of the TNF receptor-associated factor (TRAF6) family [8].
Both IRAK4 and TRAF6 activate Interferon regulatory factor
7 (IRF7) that stimulates expression of type I IFN [9]. More-
over, pDCs possess a dsRNA-independent pathway for recog-
nizing HCV and produce high levels of type I-IFN after virus
infection [10]. Since TLR expression in human pDCs is limited
to TLR7 and TLR9, TLR7-mediated pDC recognition of
HCV ssRNA may be an important antiviral pathway [11].
Meanwhile, TLR7 stimulation in virally infected hepatocytes
may inhibit HCV replication through direct activation of anti-
viral genes independent of interferon regulation factors.
Accordingly, TLR7 signaling is directly critical for the efﬁcient
control of HCV infection, not only by IFN induction, but also
through IFN-independent mechanisms. However, immune
evasion by HCV has been documented in several different host
cell types, and it has been suggested to play a key role in viral
persistence and development of chronic infection [12].
HCV employs a novel mechanism for immune evasion by
speciﬁcally targeting TLR7 expression, mRNA stability and
function [13].
Combination therapy with polyethylene glycol modiﬁed
IFN-a and ribavirin suppresses HCV replication in 40–80%
of patients. However, severe side effects are associated with
this treatment leading to poor patient compliance and sus-
tained virological response rate (SVR) for HCV-G4––the pre-
dominant genotype in Egypt––does not exceed 60%.
Moreover, the treatment of HCV-G4 non-responders, thalas-
semic patients, patients on hemodialysis and patients with
HCV-G4 recurrence after liver transplantation still represents
a signiﬁcant therapeutic challenge [14].For these reasons, it is crucial to develop alternative thera-
pies. Because TLR7 agonists can impede HCV infection both
via type I IFN and independently of IFN, they may be consid-
ered as an alternative treatment of chronic HCV infection,
especially in IFN-a-resistant patients.
Disease progression and complications of chronic hepatitis,
including the development of cirrhosis and HCC, generally
result from CTL cytotoxicity and the recruitment of inﬂamma-
tory cells to lesions in the liver [15].
The actionof INFc, secreted byactivated immune cellswhich
either reside in the liver or are recruited to the liver in response to
inﬂammation or injury, extends beyond immune modulation to
include regulation of hepatocyte apoptosis and cell cycle pro-
gression during liver disease [16,17]. IFNc might play a crucial
role in limiting HBV and HCV pathogenesis during acute infec-
tion. This is supported by the observation that IFNc suppresses
HCV replication in the HuH-7 human hepatoma cell line [18]
and inhibits HBV replication in transgenic mice [19].
Inﬂammation-induced carcinogenesis may involve abnor-
mal responses of the innate host immune system to different
kinds of antigens [20]. Down-regulation of TLR7 in hepato-
cytes has been proposed to be the exclusive mechanism
accounting for persistent hepatitis virus infection and hepato-
cyte transformation [13].
The aim of this study was to investigate the expression of
TLR7 in peripheral blood of patients with chronic HCV infec-
tions and patients with HCC, comparing it with normal indi-
viduals, and correlating it with both serum level of IFN-a
and viral load.2. Patients and methods
The study included three groups:
Group I: included 40 chronic HCV patients with positive
HCV antibodies for more than 6 months detected by the
EIA technique and positive HCV RNA detected by RT-PCR.
Group II: included 20 patients having hepatocellular carci-
noma on top of chronic HCV infection. Diagnosis is based on
focal lesion in the liver detected by radiological diagnosis and
elevated a fetoprotein.
Patients were enrolled from the Tropical Medicine Depart-
ment (inpatients and out patients).
Group III: included 20 healthy subjects with no past history
of liver disease as a control group.
All patients were subjected to
 full history taking,
 thorough clinical examination,
 laboratory investigations including: complete blood
picture, liver function tests: serum ALT, AST, albu-
min, and bilirubin level,
 abdominal ultrasonography.
Patients who had positive HBs Ag, and those with alcoholic
liver disease were excluded from the study. Informed written
consent was obtained from all participants before enrollment
in the study. The study protocol was approved by Ethics Com-
mittee of Faculty of Medicine, Ain Shams University, and has
been carried out in accordance with The Code of Ethics of The
World Medical Association (Declaration of Helsinki) for
experiments involving humans.
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Four milliliters (ml) of venous blood was collected from each
person under complete aseptic conditions and divided as
follows:
 Two milliliters was put into Ethylene Damien Tetra
Acetic Acid (EDTA) containing sterile tube; for estima-
tion of TLR7 mRNA in peripheral mononuclear cells
using the PCR technique [9].
 The remaining 2 ml was put into another sterile tube, left
to clot at room temperature, then centrifuged at
3000 rpm/min for 10 min.
Serum was separated and stored in aliquots at 20 C till
used for measurement of serum IFN-a by ELISA according
to Zhang et al. [3].
RNA extraction: RNA was extracted from PBMNCs using
QIAamp RNA Blood Mini Kits supplied by (QIAGEN) Clinic
Lab.
Principle: during the QIAamp procedure for puriﬁcation of
RNA from blood, erythrocytes were selectively lysed and leuko-
cytes were recovered by centrifugation. Leukocytes then were
lysed using highly denaturing conditions that immediately inac-
tivated RNases, allowing the isolation of intact RNA. After
homogenization of the lysate by a brief centrifugation through
a QIA shredder spin column, ethanol was added to adjust bind-
ing conditions and the sample was applied to the QIAamp spin
column. RNA was bound to the silica membrane during a brief
centrifugation step. Contaminants were washed away and total
RNA was eluted in RNase-free water for direct use. Ampliﬁca-
tion by RT-PCR was done using QuantiTect Reverse Tran-
scription kit for cDNA synthesis with integrated removal of
genomic DNA contamination for gene expression analysis.
Detection of ampliﬁcation product was done by SYBR
Green-based real-timeRT-PCR usingQuantiTect SYBRGreen
PCR kit For TLR7 the Forward primer was: TTTACCTG-
GATGGAAACCAGCTA and Reverse primer: TCAAGGCT-
GAGAAGCTGTAAGCTA and TheGAPDH-forward primer
was ATGGCT ATG ATG GAG GTC CAG and GAPDH-
reverse was TTG TCC TGC ATC TGC TTC AGC [21].
To control speciﬁcity of the ampliﬁcation products, a melt-
ing curve analysis was performed. No ampliﬁcation of nonspe-
ciﬁc products was observed. The expression of the target gene
concentration was expressed as a ratio of target to the control
gene in the same sample. Assessment of HCV load was done
with Taqman Master Mix (Applied Biosystems, Foster City,
CA). Test for Human Interferon a (IFN-a) was conducted
by quantitative ELISA Kit supplied by Bio Source Europe SA.
Principle: The microliter plate provided in this kit has been
pre-coated with an antibody speciﬁc to IFN-a. Samples were
then added to the appropriate microliter plate wells.
A biotin-conjugated polyclonal antibody preparation spe-
ciﬁc for IFN-a and Avidin conjugated to Horseradish Peroxi-
dase (HRP) were added to each micro plate well and
incubated, then a TMB (tetramethyl benzidine) substrate solu-
tion was added to each well. Only those wells that contain
IFN-a, biotin-conjugated antibody and enzyme-conjugated
Avidin exhibited a change in color. The enzyme-substrate reac-
tion was terminated by the addition of a sulphuric acid solution
and the color change was measured spectrophotometrically at awavelength of 450 nm. The concentration of IFN-a in the
samples was then determined by comparing the optical density
of the samples to the standard curve.
3. Results
This study was conducted on 80 subjects divided into three
groups:
Group I: Included 40 patients (29 males and 11 females)
with chronic liver disease due to HCV infection, with mean
age of 53.48 ± 8.31.
Group II: Included 20 patients (16 male and 4 females) with
hepatocellular carcinoma on top of chronic HCV infection,
with mean age of 58.48 ± 5.43.
Group III: Included 20 apparently healthy controls (10
males and 10 females) with mean age of 53.48 ± 8.31. The col-
lected data were revised and introduced to a PC using Statisti-
cal package for Social Science (SPSS 15.0.1 for windows; SPSS
Inc, Chicago, IL, 2001). Data were presented and suitable
analysis was done according to the type of data obtained for
each parameter. P value was considered statistically signiﬁcant
when it is <0.5 and highly signiﬁcant when it is <0.001.
Laboratory data are summarized in Table 1. The analysis
of RT-PCR and ELISA data showed a signiﬁcant decrease
in PMNCs TLR7 mRNA and serum IFN-a levels in HCV
patients compared to controls (Table 2).
In the HCV group, TLR mRNA levels showed a highly sig-
niﬁcant positive correlation with serum IFN-a levels (Fig. 1),
and a highly signiﬁcant negative correlation with viral load
(Fig. 2), while there was a highly signiﬁcant negative correla-
tion between serum IFN-a levels and viral load (Fig. 3).
Regarding the 20 patients in the HCC group, no TLR7
mRNA was detected, while serum IFN-a level was highly sig-
niﬁcantly lower than the control group (Table 3).
Regarding liver function tests, there was a highly signiﬁcant
increase in ALT, AST and bilirubin in both patients groups
compared to controls, with a highly signiﬁcant decrease in
albumin in the HCV group compared to both HCC and con-
trol groups. On the other hand, there was a highly signiﬁcant
decrease in RBCs and platelet counts in both patient groups
compared to the control group, with a highly signiﬁcant
decrease in WBCs count and Hb level in the HCV group com-
pared to HCC and control groups.
4. Discussion
Hepatitis C virus is considered to be one of the most important
devastating causes of chronic hepatitis, cirrhosis, and hepatic
cellular carcinoma [22]. In viral infection, TLR stimulation
presents a double-edged sword: it is indeed essential for trig-
gering innate and adaptive immunity against pathogens, but
TLR over-activation is known to contribute to the pathogene-
sis of chronic inﬂammatory and infectious diseases. The
strength and duration of TLR activation is thus tightly con-
trolled by multiple negative regulatory mechanisms. Research
in TLR biology has mainly focused on identiﬁcation of ligands
and signaling pathways triggered by ligand-TLR interaction
[23].
TLR7, a sensor for viral ssRNA, plays a signiﬁcant role in
anti HCV immunity responses by inducing type I IFNs and
other IFN independent antiviral mechanisms.
Table 1 Laboratory data in studied groups.
Group P Sig
Control HCV HCC
Mean ±SD Mean ±SD Mean ±SD
ALT (IU/ML) 26.55 8.28 46.43 15.68 48.45 8.33 .001 HS
AST (IU/ML) 24.00 6.48 57.42 22.36 50.75 16.01 .001 HS
T. bilirubin (mg/dl) .43 .24 1.28 .58 1.58 .60 .001 HS
D. bilirubin (mg/dl) .06 .07 .28 .11 .24 .10 .001 HS
Albumin (mg/dl) 3.49 .52 2.76 .57 3.21 .66 .001 HS
WBCs/mm3 8.88 1.71 6.36 1.49 8.40 2.53 .001 HS
RBCs/mm3 4.89 .39 4.00 .44 3.94 .58 .001 HS
Hb (mg/dl) 12.60 1.21 10.49 1.45 12.16 1.60 .001 HS
Platelets/mm3 305.2 54.12 140.60 48.29 157.60 55.96 .001 HS
ALT, alanine aminotransferase; AST, aspartate aminotransferase; Hb, hemoglobin; WBCs, white blood cells; RBCs, red blood cells.
Table 2 Comparison between HCV and control groups as
regards TLR7 mRNA and serum IFN-a levels.
Parameter Group P value Signiﬁcance
HCV (40) Controls (20)
Mean ± SD Mean ± SD
TLR7 1.05 ± 0.55 1.27 ± 0.37 0.37 S
IFN-a pg/ml 7.69 ± 7.65 9.12 ± 8.57 .041 S
390 T.A. Abdel-Raouf et al.However, HCV has strategies to avoid activation of antivi-
ral pathways by TLRs and their ligands. HCV selectively
impairs innate immunity pathways that limit HCV replication
such as type I IFNs, while at the same time generating a chronic
inﬂammatory state that causes persistent liver injury [24].Viral 
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Figure 1 Correlation between levels of TLR7mIn this study, there was a highly signiﬁcant decrease in
TLR7 mRNA expression in PBMCs among HCV patients
compared to the control group. These results are in agreement
with many previous studies. Atencia and his colleagues [9]
found a signiﬁcant down regulation in TLR3 and TLR7
mRNA levels in chronic HCV infection with cirrhosis com-
pared to healthy controls. They didn’t found this down regula-
tion in patients with liver cirrhosis not related to viral
infections (mainly of alcoholic origin). Furthermore, Taylor
and co-workers [25], observed a reduced level of expression
of TLR7 in HCV patients with poor response to interferon
therapy. Moreover, Kang et al. [26] found that the incubation
of PBMCs with HCV core proteins triggers the expression of
TLR2 and suppresses that of TLR4&TLR7. A more recent
study by Mohammed et al. [27] also demonstrated lowerload
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Figure 3 Correlation between viral load and serum IFN-a level in the HCV group.
Table 3 Comparison between serum IFN-a level in HCC and
control groups.
Parameter Group P value Signiﬁcance
HCC (20) Controls (20)
Mean ± SD Mean ± SD
IFN-a pg/ml 5.78 ± 4.2 9.12 ± 8.57 0.001 HS
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infection as compared to controls. Chang [28] postulated that
HCV down-regulates TLR7 by decreasing mRNA stability
which could facilitate evasion of host immune surveillance.
Our study revealed a highly signiﬁcant negative correlation
between TLR7 mRNA level and viral load in HCV patients.
Chang et al. [13] reported that reduction of HCV replication
increases TLR7 mRNA and protein expression, while HCV
infection produces instability of mRNA leading to low TLR7
RNA and protein expression and impairment of TLR7 signal-
ing pathway and activation of IRF7. However, Mohammed
and his co-workers [27] found no correlation between TLR7
expression and viral load or histopathological staging and
grading of the liver tissue in chronic hepatitis C patients.
Regarding serum IFN-a level, we found a signiﬁcant
decrease in the HCV group compared to the control group.
Ishii and koziel [29] demonstrated that expression of viral
NS5A protein inhibits the signaling pathway of TLR2,
TLR4, TLR7 and TLR9 by binding to the adaptor protein
MyD88 and inhibiting the recruitment of IRAK4 leading to
a decrease in MyD88-dependent signals responsible for IFN-a
production. While plasma DCs-which can produce type I
IFN 200–1000 folds more than other types of cells in blood
representing the front line HCV innate antiviral immunity-
use TLR7 for viral detection [30].
Abe et al. [31] postulated that shutting TLR7 signaling by
HCV leads to suppression of maturation and differentiation
of pDCs which are the main source of IFN-a in infected pts.
Moreover Shina and Rehermann [32] suggested that HCV
may speciﬁcally target plasma DCs, while Szabo and Mandre-
kar [33] found that TLR7, TLR8 and TLR9-induced IFN-a
production is diminished in peripheral pDCs of infected
HCV patients. In the current study, we found that serum IFN-a
level was positively correlated with TLR expression in PBMCs
and negatively correlated with viral load in HCV patients. The
same results were obtained by, Mohammed et al. [27] andAtencia et al. [9] who suggested that one of the mechanisms
leading to the chronicity of infection could be the acquisition
of an ‘‘exhausted’’ state of this antiviral machinery at the late
stages of infection.
Innate immunity plays a critical role in the development
and progression of HCC. In particular, the activation of
Toll-like receptor signaling results in the generation of immune
responses that often result in the production of pro-inﬂamma-
tory cytokines and chemokines, and could cause acute inﬂam-
mation in the liver [34].
Regarding the HCC group in this study, no TLR7 mRNA
was detected, while serum IFN-a level was signiﬁcantly lower
than the control group.
Similarly, Chang co-workers [13] detected a signiﬁcant
decrease of TLR7 expression in the presence of HCV infection
both in vivo in human HCV-infected livers and in vitro in hep-
atoma cells. They found that HCV infection in hepatoma cells
can impair expression and function of TLR7, while HCV
clearance by interferon alpha treatment or self-restriction of
viral replication through high passage number of culture cells,
restored the decreased TLR7 expression.
Furthermore, Lin and his colleagues [23] found a signiﬁcant
downregulation in TLR7 expression in cancerous regions in all
HCC liver tissues compared to adjacent normal hepatocytes.
The expression levels of TLR7 were higher in adjacent normal
liver tissue compared to tumor tissue from HBV-related, HCV-
related, and non-HBV/HCV-related HCC. They hypothesized
that IFNc induced by hepatitis virus infection signiﬁcantly
decreases TLR7 promotor activity leading to downregulation
of TLR7 gene expression resulting in immune escape and even
immunological tolerance thereby facilitating its persistence
within liver cells and modulating inﬂammatory signaling in
hepatoma cells.
In conclusion, there is evidence that down regulation of
TLR7 expression by HCV may contribute to the decrease of
IFN-a and increase in viral load in chronic HCV and HCC
patients.
These results raise the possibility that targeting TLR7 with
high afﬁnity pharmacological stimulants may be able to con-
trol HCV infection by induction of IFN-a and direct activation
of antiviral mechanisms in hepatocytes. Furthermore, they
provide insight about the potential use of TLR7 as a new set
of molecular markers for prognosis and outcomes of chronic
HCV infection and HCC. A larger scale clinical investigation
should be undertaken to determine this novel therapeutic
and prognostic approach.
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